Clinical Trials Logo

Parkinsonian Disorders clinical trials

View clinical trials related to Parkinsonian Disorders.

Filter by:

NCT ID: NCT05551377 Active, not recruiting - Parkinson Disease Clinical Trials

Head-up Tilt Sleeping to Alleviate Orthostatic Hypotension, Supine Hypertension and Nocturia in Parkinson's Disease

Start date: January 18, 2023
Phase: N/A
Study type: Interventional

Autonomic dysfunction is common and often underrecognized in Parkinson's disease (PD). Orthostatic hypotension (OH) affects up to a third of PD patients and often coincides with supine hypertension. This co-occurrence complicates pharmacological treatment as treatment of one can negatively affect the other. Head-up tilt sleeping (HUTS) could improve both. This phase II randomized controlled trial (RCT) aims to investigate the efficacy and tolerability of this understudied intervention, leading to optimal implementation strategies.

NCT ID: NCT05514106 Enrolling by invitation - Dementia Clinical Trials

MIBG in Aging and Neurologic Disorders

Start date: May 8, 2023
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate the use of a special radioactive drug called 123I-MIBG and myocardial MIBG scintigraphy. This scan may be able to help determine who may have a certain kind of neurologic disorder called Lewy Body Disease. The overall purpose of this study is to correlate myocardial MIBG scintigraphy findings with clinical diagnosis. Myocardial MIBG scintigraphy imaging will be combined with other clinical, neuropsychological and neuroimaging findings to improve the prediction for underlying Lewy Body Disease.

NCT ID: NCT05506891 Recruiting - Parkinsonism Clinical Trials

Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy

Start date: October 1, 2023
Phase: Phase 2
Study type: Interventional

α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. However, there is still a lack of research on the treatment for non-motor symptoms of α-synucleinopathy, especially autonomic dysfunctions such as orthostatic hypotension. Efficacy and safety of astragalus for non-motor symptoms of α-synucleinopathy will be assessed by an open-label self-controlled before-and-after study.

NCT ID: NCT05462080 Recruiting - Clinical trials for Movement Disorders (Incl Parkinsonism)

Correlation of Motor Metrics and Neurological Data

COMMAND
Start date: November 10, 2022
Phase:
Study type: Observational

This is a pilot study to collect data with the Ceraxis product and standard movement disorders tests in order to prove and codify potential correlations.

NCT ID: NCT05452655 Recruiting - Parkinson Disease Clinical Trials

Intensive Multidisciplinary Rehabilitation and Biomarkers in Parkinson's Disease

Start date: December 9, 2020
Phase: N/A
Study type: Interventional

Parkinson's disease (PD) is a progressive neurological disorder characterized by motor and non-motor symptoms such as rigidity, bradykinesia, resting tremor, cognitive and autonomic dysfunctions, gait and balance difficulties. The impairment of gait, balance and cognitive performances is partially responsive to dopaminergic medications. This emphasizes the importance of non-pharmacological interventions for people with PD (pwPD). Intensive multidisciplinary motor and cognitive rehabilitation has been proposed as a complementary and effective treatment for managing pwPD. Several structural and physiological mechanisms have been suggested to underpin exercise-induced neuroplastic changes in PD, such as enhanced synaptic strength and preservation of dopamine neurons. To date, studies on brain changes induced by motor and cognitive exercises in pwPD have been small-scaled and uncontrolled. Identifying accessible and measurable biomarkers for monitoring the events induced by intensive motor and cognitive rehabilitation program would help in testing the treatment effectiveness and would allow personalization of rehabilitation strategies by predicting patients' responsiveness. Based on validated clinical assessments of intensive multidisciplinary rehabilitation treatment, the project will test the ability of a new set of biomarkers to evaluate rehabilitative outcomes in a cohort of people with PD.

NCT ID: NCT05356845 Completed - Clinical trials for Parkinsonian Disorders

Oral Health, Orofacial Function and Oral Health Care in Patients With Parkinson's Disease

Start date: May 3, 2021
Phase:
Study type: Observational

Introduction: Problems with oral health (dental and oral diseases) as well as orofacial function (jaw opening, chewing and salivation problems) are significant challenges for many people with Parkinson's disease (PD). These challenges may be painful, disabling, and cause great psychosocial strain and negatively affect quality of life. Furthermore, they may contribute to an unsecure and unhealthy aging, because eating and enjoyment of food is important for both the physical and psychological wellbeing for elderly and chronically ill patients. It seems that patients with PD often find it difficult to maintain adequate oral hygiene and fail to visit the dentist, which in the end contributes to tooth loss, eating problems, poorer nutrition, social challenges and reduced quality of life. To be able to plan interventions on a larger scale more detailed knowledge and mapping is necessary on the extent of various manifestations of PD in the orofacial area, the affect on the patients and their quality of life, and how the disease develops in the orofacial area for the patient group over time. The study will clarify the challenges and problems that patients with PD have due to their disease in terms of dental and oral health and function of mouth and jaws. Such information is important both for single patients with respect to prevention and intervention and for development of community health strategies. Purpose - to investigate specific orofacial, non-motor and motor symptoms and functions as well as the oral microbiome in patients with PD compared to a control group. - to examine the quality of life related to oral health in the abovementioned groups. - to provide information on the orofacial problems in PD for the benefit of single patients with respect to prevention and intervention and for development of community health strategies. Hypotheses: It is expected that - patients with PD have more orofacial functional problems and poorer oral health than a control group without PD, and patients with late PD have more orofacial functional problems and poorer oral health than patients with early PD. - patients with PD have an altered oral microbiome compared to a control group without PD, which possibly may assist in the staging of PD. - patients with PD have poorer oral health related quality of life and home dental care than a control group without PD.

NCT ID: NCT05320250 Recruiting - Clinical trials for Parkinson's Disease and Parkinsonism

Saliva and Extracellular Vesicles for Parkinson's Disease

RaSPiD
Start date: December 15, 2021
Phase:
Study type: Observational

Rehabilitation is crucial in the treatment of people with Parkinson's disease (PD) as it can ameliorate motor and non-motor impairments, improving their clinical profile and quality of life. Considering the complex biological processes occurring in PD brain, the identification of accessible and measurable biomarkers to monitor the events induced by intensive rehabilitation would help in i)testing rehabilitation effectiveness, ii)improving the design of clinical trials and iii)personalizing the rehabilitation strategies by the prediction of patients' responsiveness. The objective of this project is the validation of Raman analysis of saliva and salivary extracellular vesicles (EV) for the differential diagnosis of Parkinson's disease (PD) and atypical Parkinsonism. The proposed diagnostic method can be integrated in the preliminary assessment and monitoring of the patient by providing a quickly and repeatable measurable biomarker. In the end, this will bring tothe personalization of the rehabilitation path and provide an indication on the outcome of the rehabilitation treatment.

NCT ID: NCT05308485 Active, not recruiting - Parkinson Disease Clinical Trials

Events Exposure as a Trigger of the Clinical Manifestations of Parkinson's Disease

Start date: January 6, 2020
Phase:
Study type: Observational

Stress has been implicated as a trigger of many diseases, throughout different mechanisms. Potentially traumatic/stressful events exposure might be a factor that triggers subclinical disabilities related to PD becoming evident to the patient. In this observational study, the investigators will evaluate with a validated events exposure questionnaire the occurrence and severity of potentially traumatic or stressful events in Parkinson's disease patients and in patients with recent-onset parkinsonism.

NCT ID: NCT05273957 Active, not recruiting - Parkinson Disease Clinical Trials

A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.

PROUD
Start date: March 29, 2021
Phase: N/A
Study type: Interventional

The present multicenter randomized study investigates whether the management of patients with parkinsonism by a nurse specialist (case-manager) can significantly improve patients' quality of life over 12 months, compared to control patients managed with the standard-of-care process. Participants will be evaluated with clinical scales testing quality of life, motor and non-motor symptoms, and the number of unscheduled hospital access throughout the course of the study.

NCT ID: NCT05222386 Recruiting - Parkinson Disease Clinical Trials

Community Outreach for Palliative Engagement -- Parkinson Disease

COPE-PD
Start date: April 26, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Telemedicine is the use of technology that allows participants to interact with a health care provider without being physically near the provider.